Gene therapy - A brief overview of the past, present, and future

被引:22
作者
Scollay, R [1 ]
机构
[1] Genteric, Alameda, CA 94501 USA
来源
NEW VISTAS IN THERAPEUTICS, FROM DRUG DESIGN TO GENE THERAPY: DRUG-RESISTANT TUBERCULOSIS, FROM MOLECULES TO MACRO-ECONOMICS | 2001年 / 953卷
关键词
gene therapy; clinical trials; trial design; cancer; cardiovascular disease; hemophilia;
D O I
10.1111/j.1749-6632.2001.tb11357.x
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Gene therapy has only recently begun to make serious progress, beginning with two approved gene therapy trials in the United States In late 1990. The death of an 18-year-old man participating in a gene therapy trial delivered a major setback in terms of public concerns, but the resulting improvements in scrutiny of trial design and ethical standards will benefit the field in the long run. The three main issues for the coming decade will be public perceptions, scale-up and manufacturing, and commercial considerations. Focusing on single-gene applications, which tend to be rarer diseases, will produce successful results sooner than the current focus on the commoner, yet more complex, cancer and heart disease.
引用
收藏
页码:26 / 30
页数:5
相关论文
共 6 条
  • [1] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS
    BLAESE, RM
    CULVER, KW
    MILLER, AD
    CARTER, CS
    FLEISHER, T
    CLERICI, M
    SHEARER, G
    CHANG, L
    CHIANG, YW
    TOLSTOSHEV, P
    GREENBLATT, JJ
    ROSENBERG, SA
    KLEIN, H
    BERGER, M
    MULLEN, CA
    RAMSEY, WJ
    MUUL, L
    MORGAN, RA
    ANDERSON, WF
    [J]. SCIENCE, 1995, 270 (5235) : 475 - 480
  • [2] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
    Cavazzana-Calvo, M
    Hacein-Bey, S
    Basile, CD
    Gross, F
    Yvon, E
    Nusbaum, P
    Selz, F
    Hue, C
    Certain, S
    Casanova, JL
    Bousso, P
    Le Deist, F
    Fischer, A
    [J]. SCIENCE, 2000, 288 (5466) : 669 - 672
  • [3] Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
    Kay, MA
    Manno, CS
    Ragni, MV
    Larson, PJ
    Couto, LB
    McClelland, A
    Glader, B
    Chew, AJ
    Tai, SJ
    Herzog, RW
    Arruda, V
    Johnson, F
    Scallan, C
    Skarsgard, E
    Flake, AW
    High, KA
    [J]. NATURE GENETICS, 2000, 24 (03) : 257 - 261
  • [4] A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
    Khuri, FR
    Nemunaitis, J
    Ganly, I
    Arseneau, J
    Tannock, IF
    Romel, L
    Gore, M
    Ironside, J
    MacDougall, RH
    Heise, C
    Randlev, B
    Gillenwater, AM
    Bruso, P
    Kaye, SB
    Hong, WK
    Kirn, DH
    [J]. NATURE MEDICINE, 2000, 6 (08) : 879 - 885
  • [5] Rosenberg SA, 1992, HUM GENE THER, V3, P57
  • [6] AN EARLY HISTORY OF GENE-TRANSFER AND THERAPY
    WOLFF, JA
    LEDERBERG, J
    [J]. HUMAN GENE THERAPY, 1994, 5 (04) : 469 - 480